Key Points
- Late molecular recurrences after 2 years in patients with CML experiencing TFR represent 14% of all molecular recurrences.
- Patients with fluctuating minimal residual disease measurements during TFR are at high risk of late molecular recurrences.
Article type:
Original publication date:
Tuesday, July 28, 2020